August 27th 2024
There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Urology Product Preview April 2014
April 16th 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.
AUA Exhibit Hall Highlights: Orlando 2014
April 2nd 2014This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
Groups slam testosterone study, call for retraction
March 31st 2014Three professional medical societies and an international group of 130 scientists and physicians have petitioned JAMA to retract a recent article that reported an association between the use of testosterone therapy and increased risk of death, heart attack, or ischemic stroke.
No link found between testosterone replacement therapy, prostate cancer risk
March 21st 2014Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.
Peyronie’s agent meets phase III study endpoints
December 2nd 2013Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
New Urology Products and Services November 2013
October 29th 2013The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.